Commentary Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/cardiology.3.031
Commentary on: Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?
Eftychia Demerouti1, Dimitrios Tsiapras1,*
- 1Non Invasive Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece
Corresponding Author
Dimitrios Tsiapras, dtsiapras@hotmail.com
Received Date: May 24, 2022
Accepted Date: June 16, 2022
Tsiapras D, Demerouti E. Commentary on: Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility? J Clin Cardiol. 2022;3(1):29-34.
Copyright: © 2022 Tsiapras D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Evaluation and Management of chronic Hypertension in Pregnancy
Chronic hypertension is present in 1-2% of pregnant women. Women with chronic hypertension are at an increased risk of maternal and perinatal complications when compared with normotensive women. It is not uncommon for the women with chronic hypertension to present first time during pregnancy and obstetricians are the first one to encounter them during antenatal checkup. Secondary hypertension is often unrecognised and misdiagnosed thus leading to improper treatment with significant risk to the mother and fetus.
Commentary on: Echocardiography in Pulmonary Arterial Hypertension: Is It Time to Reconsider Its Prognostic Utility?
Pulmonary Arterial Hypertension (PAH) represents a rare but devastating disease due to small pulmonary arterial vessels remodelling and increased pulmonary vascular resistance leading to right ventricular dysfunction, right heart failure and death.
Metformin in Patients with Chronic Heart Failure
Heart failure affects 1-2% of the adult population in developed countries and the lifetime risk of a heart failure diagnosis is 20%. Patients with heart failure have markedly reduced life expectancy, physical capacity and quality of life. One-year all-cause mortality rates for heart failure patients range between 7 and 17% and the yearly hospitalization rate can be as high as 44%.
Aldosterone Synthase Inhibitors for Treatment of Hypertension and Chronic Kidney Disease
Aldosterone excess is known to worsen hypertension and kidney function. Three selective aldosterone synthase inhibitors (ASIs) were evaluated in 3 phase 2 trials. In the first study, the ASI baxdrostat 2 mg orally once daily decreased systolic blood pressure (SBP) by 11.0 mmHg compared with placebo after 12 weeks in patients with treatment-resistant hypertension. In the second study including patients with uncontrolled hypertension, placebo-corrected reduction in SBP with lorundrostat 50 mg once daily was 9.6 mmHg after 8 weeks.